|
Number of Visitors
since May 31, 2007: 274358 |
|
| Address | |
BC Centre for Disease Control
655 W 12th Ave
Vancouver BC V5Z 4R4
|
| |
| Tel | |
604-660-6044 |
| Fax | |
604-660-2094 |
| Email | |
mel.krajden@bccdc.ca |
| |
| Biography | |
Mel Krajden is the Director of BC Hepatitis Services, as well as the Associate Director of Laboratory Services at the British Columbia Centre for Disease Control (BCCDC) and Head of the Virology section. He is also an Associate Professor of Pathology and Laboratory Medicine at the University of British Columbia. He obtained his BSc and MD (1973-80) and received Internal Medicine training at McGill University (1980-83). He completed a fellowship in Infectious Diseases at Stanford University (1983-86). He then trained as a Medical Microbiologist at the University of Toronto (1986-87). Between 1991 and 1998 he was Section Head of Virology and Serology and an Infectious Diseases consultant at The Toronto Hospital (Toronto General Hospital, The University Health Network). He is also an adjunct scientist with Canadian Blood Services.
Dr. Krajden's laboratory research relates to molecular diagnosis of viruses, using molecular markers to monitor anti-viral efficacy in vivo, and the use of molecular techniques to track microbial infections for epidemiological purposes. He has particular expertise in quantitative nucleic acid testing of viruses and inter-assay evaluation.
Since Jan 2001, Dr. Krajden has served as the Director, Hepatitis Services. This Provincial program is focused on the integration of hepatitis prevention and care services in BC. A major achievement of the Hepatitis Program has been the implementation of integrated hepatitis demonstration projects within each of BC’s five Health Authorities. These projects have linked community partners with health professionals, supporting educational training and fiscal support to provide integrated hepatitis prevention and care services. The program has also implemented a real-time link between PharmaCare and laboratories to provide cost-effective drug monitoring for hepatitis, saving approximately $400,000 per year. The hepatitis program also receives CIHR funding to support research into laboratory and clinical data linkage, model the burden of hepatitis C virus infection, and assess quality of life and costs.
In partnership with Canadian Blood Services, the Provincial Blood Coordinating Office and the BCCDC Dr. Krajden has been instrumental in initiating an Anonymized Data Linkage Project which enables privacy protected data sharing between BCCDC and Canadian Blood Services to enhance blood safety.
|
| |
| Testimony | |
|
| |
| Disciplines | |
laboratory diagnosis, nucleic acid testing, data linkage, burden of disease, modeling infectionMicrobiology; Pathology; Virology; |
[top] |
|
